Navigation Links
FDA Issues Safety Communication Regarding Increased Risk of Blood Clots with Certain Birth Control Pills
Date:9/27/2011

PHILADELPHIA, Sept. 27, 2011 /PRNewswire-USNewswire/ -- On Monday, the United States Food and Drug Administration ("FDA") said its primary results of an agency funded study suggest a 1.5 fold increase risk of blood clots for women who use drospirenone-containing birth control products, such as Yaz and Yasmin.

The safety of Yaz and Yasmin is the subject of approximately 2,000 lawsuits filed in Pennsylvania before Philadelphia Court of Common Pleas Judge Sandra Mazer Moss, Coordinating Judge of the Complex Litigation Center.  Another 7,110 lawsuits are pending in federal court before the Honorable Judge David R. Herndon, who oversees the federal multidistrict litigation (MDL).  

The lawsuits allege that Yaz and Yasmin have risks beyond those of traditional birth control pills and that Bayer over-promoted the drug without disclosing the higher risks. Bayer was warned by the Food and Drug Administration (FDA), in the fall of 2008, that its television advertisements were misleading and did not disclose the additional risks.  

The FDA announced through its website that, "initial data from an FDA-funded epidemiologic study exploring the association of blood clots with several different hormonal contraceptive products, including levonorgestrel-containing contraceptives, appear consistent with results from the 2009 and 2011 published studies. Although FDA's review is ongoing, the preliminary data from the FDA-funded study are consistent with an approximately 1.5-fold increase in the risk of blood clots for users of drospirenone-containing contraceptives compared to users of other hormonal contraceptives."

Judge Moss appointed three Pennsylvania lawyers as Liaison Counsel for the plaintiffs, including Michael M. Weinkowitz of Levin, Fishbein, Sedran & Berman, Philadelphia; Daniel N. Gallucci of RodaNast, P.C., Lancaster, and Rosemary Pinto of Feldman & Pinto, Philadelphia.  Dianne M. Nast, RodaNast, P.C. was appointed Pennsylvania Federal-State Liaison Counsel by the Honorable David R. Herndon.


'/>"/>
SOURCE RodaNast, P.C.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
2. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
3. European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
4. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
5. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
6. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
8. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
9. European Unions CHMP Issues Positive Opinion on Sugammadex
10. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
11. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... and BOSTON , ... a leading global pharmaceutical company and Paratek Pharmaceuticals, ... the development and commercialization of innovative therapies based ... 3 trials of sarecycline for the treatment of ... primary efficacy endpoints. Sarecycline is a once-daily, oral, ...
(Date:3/27/2017)... , March 27, 2017  Impax Laboratories, Inc. ... appointed Paul M. Bisaro as Impax,s President ... Company,s Board, effective March 27, 2017. Mr. Bisaro will ... as Interim President and Chief Executive Officer since December ... generic and branded pharmaceutical experience, Mr. Bisaro, 56, is ...
(Date:3/27/2017)...  PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company ... in children, today reported financial results for the ... 2016 and provided an update on its corporate ... progress during the fourth quarter of 2016 through ... safety study, and with our lead development candidate, ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... The ... supply chain professionals, will hold their first Northeast Regional AHVAP Meeting. For 2017, ... , “Increasingly, supply chain and value analysis professionals have a ‘seat at the ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... pleased to announce the launch of a months-long rebranding effort. This includes the ... , “Through focus group discussions and market research, we learned that a simple, ...
(Date:3/27/2017)... Texas (PRWEB) , ... March 27, 2017 , ... Harris ... hard of hearing, is bringing its latest products to the Deaf Seniors of America ... will have the opportunity to meet with knowledgeable ASL friendly staff from Harris Communications ...
(Date:3/24/2017)... ... 2017 , ... Vighter established its NAEMT Authorized Training Center ... Trauma Life Support (PHTLS) course scholarships to four medics assigned to the Minnesota ... cooperation with the American College of Surgeons to promote critical thinking in addressing ...
(Date:3/24/2017)... ... March 24, 2017 , ... According to a new study ... because it does not obey the rules Congress has directed the CBO to follow. ... the GOP reform would restore. Yet, it estimates a reduction in employer-based coverage due ...
Breaking Medicine News(10 mins):